Early Interim Chemotherapy Response Evaluation by F-18 FDG PET/CT in Diffuse Large B Cell Lymphoma
Abstract
:1. Introduction
2. Materials and Methods
2.1. Patients
2.2. FDG PET/CT Acquisition
2.3. Image Analysis, Response Evaluation, and Disease Status at 1 Year
2.4. Statistical Analysis
3. Results
3.1. Baseline Patient Characteristics
3.2. Visual Analysis of FDG PET/CT
3.3. Quantitative Analysis of FDG PET/CT
3.4. Comparison between Quantitative and Visual Analysis
3.5. Treatment Outcome and 1 Year Clinical Outcome
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
References
- Lee, H.; Park, H.J.; Park, E.H.; Ju, H.Y.; Oh, C.M.; Kong, H.J.; Jung, K.W.; Park, B.K.; Lee, E.; Eom, H.S.; et al. Nationwide Statistical Analysis of Lymphoid Malignancies in Korea. Cancer Res. Treat. Off. J. Korean Cancer Assoc. 2018, 50, 222–238. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Coiffier, B.; Sarkozy, C. Diffuse large B-cell lymphoma: R-CHOP failure-what to do? Hematol. Am. Soc. Hematol. Educ. Program. 2016, 2016, 366–378. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Longo, D.; Fauci, A.; Kasper, D.; Hauser, S. Harrison’s Principles of Internal Medicine, 18th ed.; McGraw-Hill: New York, NY, USA, 2011. [Google Scholar]
- Cheson, B.D.; Fisher, R.I.; Barrington, S.F.; Cavalli, F.; Schwartz, L.H.; Zucca, E.; Lister, T.A. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano classification. J. Clin. Oncol. 2014, 32, 3059–3068. [Google Scholar] [CrossRef] [PubMed]
- Tilly, H.; Vitolo, U.; Walewski, J.; da Silva, M.G.; Shpilberg, O.; Andre, M.; Pfreundschuh, M.; Dreyling, M. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2012, 23 (Suppl. 7), vii78–vii82. [Google Scholar] [CrossRef] [PubMed]
- Zelenetz, A.D.; Gordon, L.I.; Wierda, W.G.; Abramson, J.S.; Advani, R.H.; Andreadis, C.B.; Bartlett, N.; Bellam, N.; Byrd, J.C.; Czuczman, M.S.; et al. Non-Hodgkin’s lymphomas, version 2.2014. J. Natl. Compr. Cancer Netw. 2014, 12, 916–946. [Google Scholar] [CrossRef] [PubMed]
- National Comprehensive Cancer Network B-Cell Lymphomas (Version 4.2019). Available online: https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf (accessed on 9 August 2019).
- Cheson, B.D.; Pfistner, B.; Juweid, M.E.; Gascoyne, R.D.; Specht, L.; Horning, S.J.; Coiffier, B.; Fisher, R.I.; Hagenbeek, A.; Zucca, E.; et al. Revised response criteria for malignant lymphoma. J. Clin. Oncol. 2007, 25, 579–586. [Google Scholar] [CrossRef]
- Wahl, R.L.; Jacene, H.; Kasamon, Y.; Lodge, M.A. From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. J. Nucl. Med. 2009, 50 (Suppl. 1), 122S–150S. [Google Scholar] [CrossRef] [Green Version]
- Kasamon, Y.L.; Jones, R.J.; Wahl, R.L. Integrating PET and PET/CT into the risk-adapted therapy of lymphoma. J. Nucl. Med. 2007, 48 (Suppl. 1), 19s–27s. [Google Scholar]
- Barrington, S.F.; Kluge, R. FDG PET for therapy monitoring in Hodgkin and non-Hodgkin lymphomas. Eur. J. Nucl. Med. Mol. Imaging 2017, 44, 97–110. [Google Scholar] [CrossRef] [Green Version]
- Wahl, R.L.; Zasadny, K.; Helvie, M.; Hutchins, G.D.; Weber, B.; Cody, R. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: Initial evaluation. J. Clin. Oncol. 1993, 11, 2101–2111. [Google Scholar] [CrossRef]
- Hyun, O.J.; Luber, B.S.; Leal, J.P.; Wang, H.; Bolejack, V.; Schuetze, S.M.; Schwartz, L.H.; Helman, L.J.; Reinke, D.; Baker, L.H.; et al. Response to Early Treatment Evaluated with 18F-FDG PET and PERCIST 1.0 Predicts Survival in Patients with Ewing Sarcoma Family of Tumors Treated with a Monoclonal Antibody to the Insulinlike Growth Factor 1 Receptor. J. Nucl. Med. 2016, 57, 735–740. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Joo Hyun, O.; Lodge, M.A.; Wahl, R.L. Practical PERCIST: A Simplified Guide to PET Response Criteria in Solid Tumors 1.0. Radiology 2016, 280, 576–584. [Google Scholar]
- Le Gouill, S.; Casasnovas, R.O. Interim PET-driven strategy in de novo diffuse large B-cell lymphoma: Do we trust the driver? Blood 2017, 129, 3059–3070. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Pinker, K.; Riedl, C.; Weber, W.A. Evaluating tumor response with FDG PET: Updates on PERCIST, comparison with EORTC criteria and clues to future developments. Eur. J. Nucl. Med. Mol. Imaging 2017, 44, 55–66. [Google Scholar] [CrossRef]
- Han, E.J.; Joo Hyun, O.; Yoon, H.; Jung, S.E.; Park, G.; Choi, B.O.; Cho, S.G. FDG PET/CT response in diffuse large B-cell lymphoma: Reader variability and association with clinical outcome. Medicine 2016, 95, e4983. [Google Scholar] [CrossRef]
- Burggraaff, C.N.; Cornelisse, A.C.; Hoekstra, O.S.; Lugtenburg, P.J.; De Keizer, B.; Arens, A.I.J.; Celik, F.; Huijbregts, J.E.; De Vet, H.C.W.; Zijlstra, J.M. Interobserver Agreement of Interim and End-of-Treatment (18)F-FDG PET/CT in Diffuse Large B-Cell Lymphoma: Impact on Clinical Practice and Trials. J. Nucl. Med. 2018, 59, 1831–1836. [Google Scholar] [CrossRef] [Green Version]
- Andre, M.P.E.; Girinsky, T.; Federico, M.; Reman, O.; Fortpied, C.; Gotti, M.; Casasnovas, O.; Brice, P.; van der Maazen, R.; Re, A.; et al. Early Positron Emission Tomography Response-Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial. J. Clin. Oncol. 2017, 35, 1786–1794. [Google Scholar] [CrossRef]
- National Comprehensive Cancer Network Hodgkin Lymphoma (Version 2.2019). Available online: https://www.nccn.org/professionals/physician_gls/pdf/hodgkins.pdf (accessed on 9 August 2019).
- Burggraaff, C.N.; de Jong, A.; Hoekstra, O.S.; Hoetjes, N.J.; Nievelstein, R.A.J.; Jansma, E.P.; Heymans, M.W.; de Vet, H.C.W.; Zijlstra, J.M. Predictive value of interim positron emission tomography in diffuse large B-cell lymphoma: A systematic review and meta-analysis. Eur. J. Nucl. Med. Mol. Imaging 2019, 46, 65–79. [Google Scholar] [CrossRef] [Green Version]
- Sun, N.; Zhao, J.; Qiao, W.; Wang, T. Predictive value of interim PET/CT in DLBCL treated with R-CHOP: Meta-analysis. Biomed. Res. Int. 2015, 2015, 648572. [Google Scholar] [CrossRef] [Green Version]
- Kim, J.; Song, Y.S.; Lee, J.S.; Lee, W.W.; Kim, S.E. Risk stratification of diffuse large B-cell lymphoma with interim PET-CT based on different cutoff Deauville scores. Leuk. Lymphoma 2018, 59, 340–347. [Google Scholar] [CrossRef]
- Bertagna, F.; Giubbini, R.; Albano, D. Evidence-based PET for haematological tumours. In Evidence-Based Positron Emission Tomography; Treglia, G., Giovanella, L., Eds.; Springer: Cham, Switzerland, 2020; pp. 79–88. [Google Scholar]
- Yuan, L.; Kreissl, M.C.; Su, L.; Wu, Z.; Hacker, M.; Liu, J.; Zhang, X.; Bo, Y.; Zhang, H.; Li, X.; et al. Prognostic analysis of interim (18)F-FDG PET/CT in patients with diffuse large B cell lymphoma after one cycle versus two cycles of chemotherapy. Eur. J. Nucl. Med. Mol. Imaging 2019, 46, 478–488. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kostakoglu, L.; Goldsmith, S.J.; Leonard, J.P.; Christos, P.; Furman, R.R.; Atasever, T.; Chandramouly, A.; Verma, S.; Kothari, P.; Coleman, M. FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease. Cancer 2006, 107, 2678–2687. [Google Scholar] [CrossRef] [PubMed]
- Lin, C.; Itti, E.; Haioun, C.; Petegnief, Y.; Luciani, A.; Dupuis, J.; Paone, G.; Talbot, J.N.; Rahmouni, A.; Meignan, M. Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis. J. Nucl. Med. 2007, 48, 1626–1632. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Mylam, K.J.; Kostakoglu, L.; Hutchings, M.; Coleman, M.; Lamonica, D.; Czuczman, M.S.; Diehl, L.F.; Nielsen, A.L.; Jensen, P.; Loft, A.; et al. (18)F-fluorodeoxyglucose-positron emission tomography/computed tomography after one cycle of chemotherapy in patients with diffuse large B-cell lymphoma: Results of a Nordic/US intergroup study. Leuk. Lymphoma 2015, 56, 2005–2012. [Google Scholar] [CrossRef]
- Albano, D.; Bosio, G.; Pagani, C.; Re, A.; Tucci, A.; Giubbini, R.; Bertagna, F. Prognostic role of baseline 18F-FDG PET/CT metabolic parameters in Burkitt lymphoma. Eur. J. Nucl. Med. Mol. Imaging 2019, 46, 87–96. [Google Scholar] [CrossRef]
- Albano, D.; Bertoli, M.; Battistotti, M.; Rodella, C.; Statuto, M.; Giubbini, R.; Bertagna, F. Prognostic role of pretreatment 18F-FDG PET/CT in primary brain lymphoma. Ann. Nucl. Med. 2018, 32, 532–541. [Google Scholar] [CrossRef] [PubMed]
- Albano, D.; Bosio, G.; Bianchetti, N.; Pagani, C.; Re, A.; Tucci, A.; Giubbini, R.; Bertagna, F. Prognostic role of baseline 18F-FDG PET/CT metabolic parameters in mantle cell lymphoma. Ann. Nucl. Med. 2019, 33, 449–458. [Google Scholar] [CrossRef] [PubMed]
- Albano, D.; Mazzoletti, A.; Spallino, M.; Muzi, C.; Zilioli, V.R.; Pagani, C.; Tucci, A.; Rossetti, C.; Giubbini, R.; Bertagna, F. Prognostic role of baseline 18F-FDG PET/CT metabolic parameters in elderly HL: A two-center experience in 123 patients. Ann. Hematol. 2020, 99, 1321–1330. [Google Scholar] [CrossRef]
- Gormsen, L.C.; Vendelbo, M.H.; Pedersen, M.A.; Haraldsen, A.; Hjorthaug, K.; Bogsrud, T.V.; Petersen, L.J.; Jensen, K.J.; Brondum, R.; El-Galaly, T.C. A comparative study of standardized quantitative and visual assessment for predicting tumor volume and outcome in newly diagnosed diffuse large B-cell lymphoma staged with 18F-FDG PET/CT. EJNMMI Res. 2019, 9, 36. [Google Scholar] [CrossRef] [PubMed]
- Park, Y.S.; Lee, S.M.; Park, J.S.; Bae, S.K.; Shim, H.K.; Lee, W.S.; Lee, S.M. Evaluating the Predictive Ability of Initial Staging F-18 FDG PET/CT for the Prognosis of Non-Hodgkin Malignant Lymphoma Patients Who Underwent Stem Cell Transplantation. Nucl. Med. Mol. Imaging 2018, 52, 216–223. [Google Scholar] [CrossRef]
- Kim, J.; Lee, J.O.; Paik, J.H.; Lee, W.W.; Kim, S.E.; Song, Y.S. Different predictive values of interim (18)F-FDG PET/CT in germinal center like and non-germinal center like diffuse large B-cell lymphoma. Ann. Nucl. Med. 2017, 31, 1–11. [Google Scholar] [CrossRef] [PubMed]
- Choi, W.W.; Weisenburger, D.D.; Greiner, T.C.; Piris, M.A.; Banham, A.H.; Delabie, J.; Braziel, R.M.; Geng, H.; Iqbal, J.; Lenz, G.; et al. A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin. Cancer Res. 2009, 15, 5494–5502. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Variable | Number (%) |
---|---|
Age | |
Mean ± SD a (range) | 54.6 ± 14.5 years (21–81) |
≤60 | 30 (58.8) |
>60 | 21(41.2) |
Sex | |
male | 31 (60.8) |
female | 20 (39.2) |
Ann Arbor stage | |
I–II | 21 (41.2) |
III–IV | 30 (58.8) |
LDH b | |
normal | 25 (49.0) |
elevated | 26 (51.0) |
ECOG c Performance status | |
0–1 | 40 (78.4) |
2–4 | 11 (21.6) |
International Prognostic Index | |
0–1 | 17 (33.3) |
2 | 10 (19.6) |
3 | 13 (25.5) |
4–5 | 11 (21.6) |
Number of extranodal site | |
0–1 | 22 (43.1) |
≥2 | 29 (56.9) |
Subtype | |
GCB d | 20 (39.2) |
Non-GCB | 25 (49.0) |
Unknown | 6 (11.8) |
Variable | Early Responder (n = 24) | Late Responder (n = 18) | p |
---|---|---|---|
Age | |||
Mean ± SD a (range) | 55.4 ± 15.4 (30–81) | 53.1 ± 14.1 (21–70) | 0.614 |
≤60 | 14 | 11 | 0.856 |
>60 | 10 | 7 | |
Sex | |||
male | 16 | 9 | 0.276 |
female | 8 | 9 | |
Ann Arbor stage | |||
I–II | 12 | 7 | 0.474 |
III–IV | 12 | 11 | |
LDH b | 0.060 e | ||
normal | 16 | 6 | |
elevated | 8 | 12 | |
ECOG c Performance status | 0.403 | ||
0–1 | 21 | 14 | |
2–4 | 3 | 4 | |
International Prognostic Index | 0.641 | ||
0–1 | 11 | 5 | |
2 | 5 | 4 | |
3 | 5 | 5 | |
4–5 | 3 | 4 | |
Number of extranodal site | 0.212 | ||
0–1 | 14 | 7 | |
≥2 | 10 | 11 | |
Subtype | 0.393 | ||
GCB d | 8 | 8 | |
Non-GCB | 13 | 9 | |
Not specified | 3 | 1 |
Compared PET Images | SULpeak | MTV | ||
---|---|---|---|---|
absΔSUL | %ΔSUL | absΔMTV (cm3) | %ΔMTV | |
PET∆0–1 | | | | |
PET∆0–3 | ||||
PET∆0–6 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Park, H.L.; Han, E.J.; O, J.H.; Choi, B.-O.; Park, G.; Jung, S.-E.; Yahng, S.-A.; Eom, K.-S.; Cho, S.-G.; on behalf of Catholic University Lymphoma Group. Early Interim Chemotherapy Response Evaluation by F-18 FDG PET/CT in Diffuse Large B Cell Lymphoma. Diagnostics 2020, 10, 1002. https://doi.org/10.3390/diagnostics10121002
Park HL, Han EJ, O JH, Choi B-O, Park G, Jung S-E, Yahng S-A, Eom K-S, Cho S-G, on behalf of Catholic University Lymphoma Group. Early Interim Chemotherapy Response Evaluation by F-18 FDG PET/CT in Diffuse Large B Cell Lymphoma. Diagnostics. 2020; 10(12):1002. https://doi.org/10.3390/diagnostics10121002
Chicago/Turabian StylePark, Hye Lim, Eun Ji Han, Joo Hyun O, Byung-Ock Choi, Gyeongsin Park, Seung-Eun Jung, Seung-Ah Yahng, Ki-Seong Eom, Seok-Goo Cho, and on behalf of Catholic University Lymphoma Group. 2020. "Early Interim Chemotherapy Response Evaluation by F-18 FDG PET/CT in Diffuse Large B Cell Lymphoma" Diagnostics 10, no. 12: 1002. https://doi.org/10.3390/diagnostics10121002
APA StylePark, H. L., Han, E. J., O, J. H., Choi, B.-O., Park, G., Jung, S.-E., Yahng, S.-A., Eom, K.-S., Cho, S.-G., & on behalf of Catholic University Lymphoma Group. (2020). Early Interim Chemotherapy Response Evaluation by F-18 FDG PET/CT in Diffuse Large B Cell Lymphoma. Diagnostics, 10(12), 1002. https://doi.org/10.3390/diagnostics10121002